Dong-A Pharm's Stillen witnessing successful launching in market

Published: 2003-12-16 07:00:00

Updated: 2003-12-16 07:00:00

Dong-A Pharm said that its own new anti-ulcerant drug Stillen derived from natural substances has shown brisk sales of 7.0 billion won since the first launching on December of last year, thanks to superior efficacy and intensive marketing in the domestic market where Korean-type natural drugs can...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK